In an adult patient with pruritus secondary to hyperbilirubinemia, what treatment options are available besides cholestyramine?

Treatment Options for Pruritus Related to Hyperbilirubinemia (Besides Cholestyramine)

Rifampicin should be your first-line treatment for hepatic pruritus related to hyperbilirubinemia, starting at 150 mg twice daily and titrating up to 600 mg twice daily as needed. 1

Evidence-Based Treatment Algorithm

First-Line: Rifampicin

• Start at 150 mg twice daily, increase to maximum 600 mg twice daily 1
• Two meta-analyses of RCTs demonstrate rifampicin effectively reduces hepatic pruritus with a Strength of recommendation A; Level of evidence 1+ 1
• Rifampicin showed no increased side-effects compared to placebo, unlike opioid antagonists 1, 2
• Monitor hepatotoxicity with serum liver tests and inform patients about discoloration of secretions (urine, tears, sweat will turn orange-red) 1
• The British Association of Dermatologists explicitly states rifampicin should now be the drug of first choice, relegating cholestyramine to second-line 1

Second-Line: Sertraline

• Dose: 75-100 mg daily orally 1
• One small RCT supports its use with good tolerability 1
• Recommended as third-line in guidelines but should be considered before opioid antagonists due to better side-effect profile 1
• Mechanism remains unclear but clinically effective 1

Third-Line: Opioid Antagonists

• Naltrexone 50 mg daily orally (start at 25 mg to minimize withdrawal-like reactions) 1
• Alternative: Nalmefene 0.25-1 mg/kg per day intravenously 1
• Meta-analysis confirms both opioid antagonists and rifampicin reduce pruritus 1, 2
• Major caveat: Opioid antagonists have significantly more side-effects than cholestyramine and rifampicin, including opiate withdrawal-like reactions on initiation (pain, confusion, agitation) 1, 2
• Number needed to harm = 2.6, meaning approximately 1 in 3 patients will experience adverse effects 2
• Consider IV naloxone induction phase with rapid dose escalation before converting to oral naltrexone to ameliorate withdrawal symptoms 1

Fourth-Line: Other Bile Acid Sequestrants

• Colestipol or colesevelam (alternative anion exchange resins) 1
• These bind bile salts in the gut lumen, preventing absorption in the terminal ileum 1
• Must be spaced at least 4 hours away from other medications to avoid interference with absorption 1

Fifth-Line Options

• Bezafibrate (PPAR agonist) - emerging evidence in fibrosing cholangiopathies 3, 4
• Systemic agents: dronabinol, phenobarbitone, propofol 1
• Topical tacrolimus ointment 1
• Novel agents: ileal bile acid transporter inhibitors, autotaxin inhibitors, lysophosphatidic acid metabolism blockers 1, 3, 4

Phototherapy

• Broadband UVB (BB-UVB) or combined UVA and UVB may provide temporary relief 1
• Strength of recommendation D for cholestatic pruritus 1

Invasive/Last Resort Options

• Extracorporeal albumin dialysis, plasmapheresis, bile duct drainage for resistant cases 1
• Liver transplantation is effective but should only be considered when all available interventions have failed 1

Critical Pitfalls to Avoid

Do NOT use gabapentin for hepatic pruritus - explicitly contraindicated with Strength of recommendation D 1. While gabapentin is effective for uremic pruritus, it has no role in hepatic pruritus 1.

Do NOT use ondansetron routinely - two early RCTs showed benefit, but two more recent RCTs did not, making it difficult to support routine use 1

Do NOT use antihistamines - lack of efficacy in cholestatic pruritus 1

Do NOT use phenobarbital - excessive side-effect profile outweighs limited efficacy 1

Addressing the Underlying Cause

In patients with large bile duct obstruction, restoration of biliary drainage often provides prompt resolution of symptoms 1. Consider ultrasound, ERCP, or MRCP to evaluate for obstruction 1.

Strength of Evidence Considerations

The evidence base for cholestatic pruritus treatments is notably weak: most studies have small sample sizes (median n=18), 20 studies are over 20 years old, and only 25 were RCTs 5. Cholestyramine, despite being traditionally considered first-line, was assessed in only 6 studies (2 RCTs) with just 56 PBC patients and 2 PSC patients, with efficacy demonstrated in only 3 studies, two of which had high risk of bias 5. This explains why current guidelines now prioritize rifampicin, which has stronger meta-analytic support 1, 2.